基于“象思维”的清火通络方联合索拉非尼治疗肝癌疗效评价

Evaluation of Therapeutic Effect of Qinghuo Tongluo Prescription Combined with Sorafenib on Liver Cancer Based on “Image Thinking”

目的观察清火通络方联合索拉菲尼治疗晚期肝癌患者的临床疗效。方法选取我科2015年12月—2017年12月诊治的晚期原发性肝癌患者66例,分为对照组(索拉菲尼)33例,治疗组(清火通络方+索拉菲尼)33例。比较两组的实验室指标、实体瘤疗效、体力状况及毒副反应。结果治疗后3个月,治疗组治疗后降低甲胎蛋白效果优于对照组(P<0.05),而对照组治疗后恢复肝功能效果优于治疗组(P<0.05)。治疗组临床受益率显著高于对照组(P<0.05),而治疗组腹泻、恶心呕吐、乏力等不良反应发生率均明显高于对照组(P<0.05)。结论清火通络方联合索拉非尼治疗晚期原发性肝癌患者临床疗效良好,同时为进一步加强护肝作用及减轻药物毒副反应,应在原方基础上佐以疏肝健脾之品,并根据不同的个体灵活辨证治疗。

Objective To observe the curative effect of Qinghuo Tongluo prescription combined with sorafenib in treatment of advanced liver cancer. Methods 66 cases of patients with advanced liver cancer were randomly divided into treatment group and control group,33 cases in each group. Control group was treated with sorafenib,treatment group received Qinghuo Tongluo prescription on the basis of control group. The laboratory indicators,response evaluation in solid tumors,performance status,toxic and side effect of the two groups were compared. Results 3 months after treatment,the-fetal protein of treatment group was lower than that of control group(P<0.05),while the liver function of control group was better than that of treatment group(P<0.05). The clinical benefit rate of treatment group was significantly higher than that of control group(P<0.05),however,the incidence of diarrhea,nausea and vomiting and lacking in strength was significantly higher in treatment group than that in control group(P<0.05). Conclusion The curative effect of Qinghuo Tongluo prescription in treatment of patients with advanced liver cancer is good. In addition,to strengthen the effect of protecting liver and reduce the adverse drug reaction,drugs thatrelieing liver and reinforcing spleen should be added based on primary prescription,and flexibly according to different individuals.